Leerink Partners analyst Marc Goodman reiterated a Buy rating on Belite Bio, Inc. ADR today. The company’s shares opened today at $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Goodman covers the Healthcare sector, focusing on stocks such as Alkermes, ACADIA Pharmaceuticals, and Biogen. According to TipRanks, Goodman has an average return of 13.1% and a 54.08% success rate on recommended stocks.
Belite Bio, Inc. ADR has an analyst consensus of Strong Buy, with a price target consensus of $96.00.
The company has a one-year high of $86.53 and a one-year low of $49.00. Currently, Belite Bio, Inc. ADR has an average volume of 49.46K.
Read More on BLTE:
Disclaimer & DisclosureReport an Issue
- Leerink bullish on Belite Bio, says tinlarebant news another positive data point
- Belite Bio announces China’s NMPA agreed to accept NDA for Tinlarebant
- Belite Bio price target lowered to $98 from $100 at H.C. Wainwright
- Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position
- Belite Bio completes Phase 3 DRAGON trial of Tinlarebant
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
